These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 35396830

  • 21. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
    Naqash AR, Appah E, Yang LV, Muzaffar M, Marie MA, Mccallen JD, Macherla S, Liles D, Walker PR.
    J Immunother Cancer; 2019 Jul 05; 7(1):169. PubMed ID: 31277704
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Pregnancy and delivery in an advanced cancer survivor with immune checkpoint inhibitor-induced type 1 diabetes: a case report.
    Sugai K, Miwa T, Kojima J, Ueda Y, Tsukahara K, Nishi H, Suzuki R.
    Endocrine; 2024 Aug 05; 85(2):593-597. PubMed ID: 38502365
    [Abstract] [Full Text] [Related]

  • 24. Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review.
    Hong AR, Yoon JH, Kim HK, Kang HC.
    Front Endocrinol (Lausanne); 2020 Aug 05; 11():14. PubMed ID: 32047478
    [Abstract] [Full Text] [Related]

  • 25. Immune Checkpoint Inhibitors-Associated Diabetes and Ketoacidosis Were Found in FDA Adverse Event Reporting System: A Real-World Evidence Database Study.
    Han M, Jiang L, Zhao B, Liu X, Yang C, Chen W.
    Endocr Pract; 2024 Sep 05; 30(9):887-892. PubMed ID: 38876180
    [Abstract] [Full Text] [Related]

  • 26. Fulminant ACTH decrease following diabetic ketoacidosis induced by immune checkpoint inhibitor combination therapy with nivolumab and ipilimumab: A case report.
    Iesaka H, Kameda H, Miya A, Nomoto H, Cho KY, Nakamura A, Abe T, Shinohara N, Atsumi T.
    Medicine (Baltimore); 2023 Dec 22; 102(51):e36664. PubMed ID: 38134115
    [Abstract] [Full Text] [Related]

  • 27. New-onset type 1 diabetes mellitus as a delayed immune-related event after discontinuation of nivolumab: A case report.
    Seo JH, Lim T, Ham A, Kim YA, Lee M.
    Medicine (Baltimore); 2022 Sep 02; 101(35):e30456. PubMed ID: 36107574
    [Abstract] [Full Text] [Related]

  • 28. Safety and Efficacy of Extended Interval Dosing for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer During the COVID-19 Pandemic.
    Hijmering-Kappelle LBM, Hiltermann TJN, Bensch F.
    Clin Lung Cancer; 2022 Mar 02; 23(2):143-150. PubMed ID: 35034861
    [Abstract] [Full Text] [Related]

  • 29. Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
    Isono T, Kagiyama N, Takano K, Hosoda C, Nishida T, Kawate E, Kobayashi Y, Ishiguro T, Takaku Y, Kurashima K, Yanagisawa T, Takayanagi N.
    Thorac Cancer; 2021 Jan 02; 12(2):153-164. PubMed ID: 33201587
    [Abstract] [Full Text] [Related]

  • 30. Identification of Immune Checkpoint Inhibitor-Induced Diabetes.
    Ruiz-Esteves KN, Shank KR, Deutsch AJ, Gunturi A, Chamorro-Pareja N, Colling CA, Zubiri L, Perlman K, Ouyang T, Villani AC, Florez JC, Gusev A, Reynolds KL, Miller KK, Udler MS, Sise ME, Rengarajan M.
    JAMA Oncol; 2024 Oct 01; 10(10):1409-1416. PubMed ID: 39207773
    [Abstract] [Full Text] [Related]

  • 31. Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors.
    Im Y, Lee J, Kim SJ, Koh WJ, Jhun BW, Lee SH.
    Respir Med; 2020 Jan 01; 161():105853. PubMed ID: 32056727
    [Abstract] [Full Text] [Related]

  • 32. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis.
    Xu C, Chen YP, Du XJ, Liu JQ, Huang CL, Chen L, Zhou GQ, Li WF, Mao YP, Hsu C, Liu Q, Lin AH, Tang LL, Sun Y, Ma J.
    BMJ; 2018 Nov 08; 363():k4226. PubMed ID: 30409774
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes.
    Chae YK, Chiec L, Mohindra N, Gentzler R, Patel J, Giles F.
    Cancer Immunol Immunother; 2017 Jan 08; 66(1):25-32. PubMed ID: 27761609
    [Abstract] [Full Text] [Related]

  • 38. Landscape of immune checkpoint inhibitor-related adverse events in Chinese population.
    Li L, Li G, Rao B, Dong AH, Liang W, Zhu JX, Qin MP, Huang WW, Lu JM, Li ZF, Wu YZ.
    Sci Rep; 2020 Sep 23; 10(1):15567. PubMed ID: 32968172
    [Abstract] [Full Text] [Related]

  • 39. [Third degree atrio-ventricular blockade during a myocarditis occurring under anti-PD1 : Case report and literature review].
    Prevel R, Colin G, Calès V, Renault PA, Mazieres J.
    Rev Med Interne; 2020 Apr 23; 41(4):284-288. PubMed ID: 31983550
    [Abstract] [Full Text] [Related]

  • 40. Predictors of the Onset of Type 1 Diabetes Obtained from Real-World Data Analysis in Cancer Patients Treated with Immune Checkpoint Inhibitors.
    Takada S, Hirokazu H, Yamagishi K, Hideki S, Masayuki E.
    Asian Pac J Cancer Prev; 2020 Jun 01; 21(6):1697-1699. PubMed ID: 32592366
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.